The relationship of hypertriglyceridemia and left ventricular remodeling types in patients with chronic kidney disease


Cite item

Full Text

Abstract

Aim. To assess the relationship between hypertriglyceridemia (THG) and left ventricular remodeling types in patients with chronic kidney disease(CKD). Materials and methods. A total of 152 patients with CKD from stages 1 to 3 were examined, 98 of them with CKD without THG (subgroup 1) and 54 with CKD and THG. All patients were assessed for the parameters of anthropometry, hemodynamics, lipid spectrum, uric acid, calcium, C-reactive protein (CRP), and serum cystatin C measurement with calculation of glomerular filtration rate. The parameters of vascular stiffness (augmentation index and stiffness) and echocardiography are analyzed. Results and discussion. In the 2nd subgroup (CKD + THG), the number of patients suffering from type 2 diabetes, a stable form of coronary heart disease, gout, and their combination with hypertension, as well as cerebrovacular disorders and hyperuricemia was significantly higher compared with patients with CKD without GTG (p<0.05). Persons with chronic obstructive pulmonary disease, chronic pyelonephritis were significantly more common in the 1st group (p<0.05). In the 2nd group, the BMI (30.1±5.4 kg/m2 vs. 28.1±5.8 kg/m2; p=0.049), the thickness of the posterior wall of the left ventricle (LV) (0.95±0,18 cm vs. 0.89±0.16 cm; p=0.040), the number of patients with a concentric type of remodeling (12.9% vs. 2.0%; p<0.05) and LV hypertrophy (51.8% vs. 26,5%; p=0.005), as well as with a high content of CRP in serum was significantly higher compared with the 1st group. In addition, the concentration of total cholesterol (5.61 [4.82; 6.57] mmol/l vs. 4.77 [4.08; 5.35] mmol/l; p=0.001), low - density lipoprotein cholesterol (cholesterol LDL) (3.49 [3.00; 4.52] mmol/l vs. 3.13 [2.67; 3.86] mmol/l; p=0.031) and uric acid (0.439±0.150 mmol/l vs. 0.376±0.109 mmol/l; p=0.005) serum was significantly higher than similar indicators of the 1st group. In patients with CKD and without THG, the following parameters influenced the magnitude of glomerular filtration rate (GFR): augmentation index (R²=37%; p=0.024), indexed left ventricular myocardial mass (LVMI) (R²=37%; p=0.005), concentrations of uric acid (R²=37%; p=0.009) and serum LDL cholesterol (R²=37%; p=0.002). In the subgroup of patients with CKD without THG, the systolic level (R²=12%; p=0.046) and diastolic blood pressure (BP) (R²=12%; p=0.045), uric acid concentration (R²=12%; p=0.005) and serum LDL (R²=12%; p=0.006). Then whereas the factors affecting the index of LVMI in patients of the 1st subgroup were the augmentation index (R²=19; p=0.045) and the GFR value (R²=19; p=0.038). In the 2nd subgroup, the factors affecting LVMI is the systolic (R²=28; p=0.016) and diastolic blood pressure (R²=28; p=0.023), augmentation index (R²=28; p=0.041), uric acid content (R²=28; p=0.020), LDL cholesterol (R²=28; p=0.032), triglycerides (R²=28; p=0.017) and the level of GFR (R²=28; p=0.007). Conclusion. In CKD with THG, the concentric type of remodeling and left ventricular hypertrophy are significantly more common. In patients with CKD and THG, the frequency of hyperuricemia and an increase in serum CRP was significantly higher. In CKD and THG, the factors affecting the glomerular filtration rate are the values of augmentation index, uric acid concentration, low serum lipoprotein cholesterol and indexed left ventricular myocardial mass. In patients with CKD and THG, the level of systolic and diastolic blood pressure, augmentation index, uric acid concentration and low - density lipoprotein cholesterle had the greatest influence on the value of the indexed mass of the left ventricular myocardium.

About the authors

I. T Murkamilov

Akhunbaev Kyrgyz State Medical Academy; Kyrgyz-Russian Slavic University named after the first President of Russia B.N. Yeltsin

Email: murkamilov.i@mail.ru
к.м.н., председатель правления Общества специалистов по хронической болезни почек Кыргызстана, и.о. доц. каф. факультетской терапии КГМА им. И.К. Ахунбаева; тел.: +9(9655)722-19-83 Bishkek, Kyrgyzstan

I. S Sabirov

Kyrgyz-Russian Slavic University named after the first President of Russia B.N. Yeltsin

д.м.н., проф., член правления Общества специалистов по хронической болезни почек Кыргызстана, зав. каф. терапии №2 специальности «Лечебное дело» КРСУ им. Б.Н. Ельцина Bishkek, Kyrgyzstan

V. V Fomin

Sechenov First Moscow State Medical University (Sechenov University)

член-корр. РАН, д.м.н., проф., зав. каф. факультетской терапии № 1, проректор по клинической работе и дополнительному профессиональному образованию ФГАОУ ВО «Первый МГМУ им. И.М. Сеченова» Moscow, Russi

K. A Aitbaev

Scientific Research Institute of Molecular Biology and Medicine

д.м.н., проф., член правления Общества специалистов по хронической болезни почек Кыргызстана, зав. лаб. патологической физиологии НИИ молекулярной биологии и медицины Bishkek, Kyrgyzstan

Zh. A Murkamilova

Center for Family Medicine №7

врач-нефролог, терапевт Центра семейной медицины №7 Bishkek, Kyrgyzstan

References

  1. Мухин Н.А. Нефрология. Национальное руководство. Краткое издание. М.: ГЭОТАР-Медиа, 2018. 608 с.
  2. Моисеев В.С., Мухин Н.А., Смирнов А.В. и др. Сердечно - сосудистый риск и хроническая болезнь почек: стратегии кардио - нефропротекции. Российский кардиологический журнал. 2014;(8):7-37.
  3. Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Orsi E. Hypertriglyceridemia is independently associated with renal, but not retinal complications in subjects with type 2 diabetes: a cross - sectional analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One. 2015;10(5):e0125512. doi: 10.1371/journal.pone.0125512
  4. Tannock L. Dyslipidemia in chronic kidney disease. Endotext [Internet]. MDText.com, Inc., 2018.
  5. Bhowmik D, Tiwari S.C. Metabolic syndrome and chronic kidney disease. Indian J Nephrol. 2008;18(1):1-4. doi: 10.4103/0971-4065.41279
  6. Blaton V. Dyslipidemia at chronic renal failure. EJIFCC. 2009;20(1):59-66. PMID: 27683328
  7. Волгина Г.В. Гипертрофия левого желудочка сердца у больных с додиализной хронической почечной недостаточностью. Кардиоваскулярная терапия и профилактика. 2002;(4):68-75.
  8. Wu Q.S, He Q, He J.Q, Chao J, Wang W.Y, Zhou Y, Chen J.F. The role of mitofilin in left ventricular hypertrophy in hemodialysis patients. Renal Failure. 2018;40(1):252-8. doi: 10.1080/0886022X.2018.1456455
  9. Томилина Н.А., Гендлин Г.Е., Жидкова Д.А., Тронина О.А., Федорова Н.Д. Гипертрофия миокарда левого желудочка после трансплантации почки: факторы риска и возможности регресса. Терапевтический архив. 2009;81(8):42-8.
  10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
  11. Catapano A.L, Graham I, De Backer G и др. Рекомендации ЕОК/ЕОА по диагностике и лечению дислипидемий 2016. Российский кардиологический журнал. 2017;(5):7-77. doi: 10.15829/1560-4071-2017-5-7-77
  12. Елисеев М.С. Новые международные рекомендации по диагностике и лечению подагры. Научно - практическая ревматология. 2014;52(2):141-6. doi: 10.14412/1995-4484-2014-141-146
  13. Hoek F.J, Kemperman F.A, Krediet R.T. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular fi ltration rate. Nephrol Dial Transplant. 2003;18(10):2024-31. doi: 10.1093/ndt/gfg349
  14. Парфенов А.С. Ранняя диагностика сердечно - сосудистых заболеваний с использованием аппаратно - программного комплекса «Ангиоскан-01». Поликлиника. 2012;2(1):70-4.
  15. Teichholz L.E, Kreulen T, Herman M.V, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic - angiographic correlations in the presence or absence of asynergy. Am J Cardiol. 1976;37(1):7-11. doi: 10.1016/0002-9149(76)90491-4
  16. Devereux R.B, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation. 1977;55(4):613-8. PMID: 138494
  17. Williams B, Mancia G, Spiering W, Rosei E.A, Azizi M, Burnier M, Kahan T. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953-2041. doi: 10.1097/HJH.0000000000001940
  18. Колина И.Б., Ставровская Е.В., Шилов Е.М. Дислипидемия и хронические прогрессирующие заболевания почек. Терапевтический архив. 2004;76(9):75-7.
  19. Bulbul M.C, Bulbul M.C, Dagel T, Afsar B, Ulusu N.N, Kuwabara M, Covic A, Kanbay M. Disorders of lipid metabolism in chronic kidney disease. Blood Purification. 2018;46(2):144-52. doi: 10.1159/000488816
  20. Аронов Д.М., Лупанов В.П. Некоторые аспекты патогенеза атеросклероза. Атеросклероз и дислипидемии. 2011;1(2):48-56.
  21. Chapman M.J, Ginsberg H.N, Amarenco P, Andreotti F, Borén J, Catapano A.L, Lesnik P. Triglyceride - rich lipoproteins and high - density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart J. 2011;32(11):1345-61. doi: 10.1093/eurheartj/ehr112
  22. Муркамилов И.Т., Фомин В.В., Айтбаев К.А. и др. Содержание цистатина С плазмы крови и его взаимосвязь с аугментационным индексом и центральным артериальным давлением у пациентов терапевтического профиля. Клиническая нефрология. 2018;(3):31-40 [. doi: 10.18565/nephrology.20183.31-40
  23. Lanktree M.B, Thériault S, Walsh M, Paré G. HDL cholesterol, LDL cholesterol, and triglycerides as risk factors for CKD: a Mendelian Randomization Study. Am J Kidney Dis. 2018;71(2):166-72. doi: 10.1053/j.ajkd.2017.06.011
  24. Mottram P.M, Haluska B.A, Leano R, Carlier S, Case C, Marwick T.H. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart disease. Heart. 2005;91(12):1551-6. doi: 10.1136/hrt.2004.046805
  25. Badimon L, Peña E, Arderiu G, Padró T, Slevin M, Vilahur G, Chiva-Blanch G. C-reactive protein in atherothrombosis and angiogenesis. Frontiers Immunol. 2018;9:430. doi: 10.3389/fimmu.2018.00430
  26. O'rourke M. Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension. 1990;15(4):339-47. doi: 10.1161/01.HYP.15.4.339
  27. Nardi E, Geraci G, Schillaci M.K, Cottone S. The relationships between lipid ratios and arterial stiffness. J Clin Hypertens. 2017;19(8):777-9. doi: 10.1111/jch.13030
  28. London G.M. Arterial stiffness in chronic kidney disease and end - stage renal disease. Blood Purification. 2018;45(1-3):154-8. doi: 10.1159/000485146
  29. Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. BioMed Res Intern. 2014;2014:937398. doi: 10.1155/2014/937398
  30. Кобалава Ж.Д., Котовская Ю.В., Сафарова А.Ф. и др. Эхокардиографическая оценка фиброза миокарда у молодых мужчин с артериальной гипертонией и разными типами ремоделирования левого желудочка. Кардиология. 2011;51(2):34-9.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies